Allena Pharma’s kidney stone-preventing enzyme attracts $25M
Kidney stones are on the rise. One cause is a condition called hyperoxaluria – a potentially serious metabolic disorder that’s found in about 20-30 percent of patients with recurrent stones. It that lead to chronic kidney disease, end-stage renal disease and dialysis. To date, there’s no approved therapy to treat hyperoxaluria. An enzyme that can degrade oxalates – the […]